Abstract
Background: Renal disease is a serious health problem, with increasing incidence and prevalence. Oxidative stress and inflammation play a key role in the pathogenesis and progression of renal disease. Therefore, therapeutic approaches to decrease oxidative stress should be of interest.
Objective: This review aims to provide a comprehensive and updated overview of the protective mechanisms mediated by Nrf2 (nuclear factor erythroid 2–related factor 2), a description of novel compounds that target Nrf2, its effectiveness to prevent renal disease and the on-going clinical trials for this pathological condition.
Methods: We undertook a structured search of bibliographic databases for peer-reviewed research in literature about Nrf2 activators and renal disease.
Results: The transcription factor Nrf2 is an emerging regulator of cellular resistance to oxidants and inflammation. Nrf2 controls the basal and induced expression of a couple of cytoprotective and antiinflammatory genes that regulate the physiological and pathophysiological outcomes of oxidant exposure. We have analyzed numerous findings showing that Nrf2 induction protects against oxidative stress and modulates inflammation in acute kidney injury and chronic kidney disease progression. However, few clinical trials have been performed in humans. Recent studies suggested that renoprotective effects of Nrf2 activation are observed at low doses, whereas harmful effects appear at higher concentrations.
Conclusion: The findings of this review confirm that novel studies are necessary to address whether Nrf2-targeting may be a safe therapeutic approach to decrease renal disease progression in humans.
Keywords: Nrf2, oxidation, inflammation, acute and chronic kidney injury, renal damage, therapy.
Current Medicinal Chemistry
Title:Targeting Nrf2 in Protection Against Renal Disease
Volume: 24 Issue: 33
Author(s): Melania Guerrero-Hue, Victor Farre-Alins , Alejandra Palomino-Antolin, Esther Parada, Alfonso Rubio-Navarro, Jesus Egido , Javier Egea*Juan A. Moreno*
Affiliation:
- Instituto de Investigacion Sanitaria, Servicio de Farmacologia Clinica, Hospital Universitario de la Princesa, Madrid, Spain; Instituto Teofilo Hernando, Department of Pharmacology, Universidad Autonoma de Madrid, C/Arzobispo Morcillo 4, 28029 Madrid,Spain
- Renal, Vascular and Diabetes Research Laboratory. IIS-Fundacion Jimenez Diaz. Av. Reyes Catolicos 2, 28040-Madrid,Spain
Keywords: Nrf2, oxidation, inflammation, acute and chronic kidney injury, renal damage, therapy.
Abstract: Background: Renal disease is a serious health problem, with increasing incidence and prevalence. Oxidative stress and inflammation play a key role in the pathogenesis and progression of renal disease. Therefore, therapeutic approaches to decrease oxidative stress should be of interest.
Objective: This review aims to provide a comprehensive and updated overview of the protective mechanisms mediated by Nrf2 (nuclear factor erythroid 2–related factor 2), a description of novel compounds that target Nrf2, its effectiveness to prevent renal disease and the on-going clinical trials for this pathological condition.
Methods: We undertook a structured search of bibliographic databases for peer-reviewed research in literature about Nrf2 activators and renal disease.
Results: The transcription factor Nrf2 is an emerging regulator of cellular resistance to oxidants and inflammation. Nrf2 controls the basal and induced expression of a couple of cytoprotective and antiinflammatory genes that regulate the physiological and pathophysiological outcomes of oxidant exposure. We have analyzed numerous findings showing that Nrf2 induction protects against oxidative stress and modulates inflammation in acute kidney injury and chronic kidney disease progression. However, few clinical trials have been performed in humans. Recent studies suggested that renoprotective effects of Nrf2 activation are observed at low doses, whereas harmful effects appear at higher concentrations.
Conclusion: The findings of this review confirm that novel studies are necessary to address whether Nrf2-targeting may be a safe therapeutic approach to decrease renal disease progression in humans.
Export Options
About this article
Cite this article as:
Guerrero-Hue Melania , Farre-Alins Victor , Palomino-Antolin Alejandra , Parada Esther , Rubio-Navarro Alfonso , Egido Jesus, Egea Javier *, Moreno A. Juan*, Targeting Nrf2 in Protection Against Renal Disease, Current Medicinal Chemistry 2017; 24 (33) . https://dx.doi.org/10.2174/0929867324666170511120814
DOI https://dx.doi.org/10.2174/0929867324666170511120814 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Application of Resveratrol in Diabetes: Rationale, Strategies and Challenges
Current Molecular Medicine Targeting Mitochondrial Oxidative Stress Through Lipoic Acid Synthase: A Novel Strategy to Manage Diabetic Cardiovascular Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry The Ignored Role of Intraoperative Hypotension in Producing Postoperative Acute Kidney Injury-An Obligatory Appeal for More Preventative Nephrology
Current Hypertension Reviews Pericyte Loss in Diabetic Retinopathy: Mechanisms and Consequences
Current Medicinal Chemistry Uric acid and Metabolic Syndrome: What is the Relationship?
Current Rheumatology Reviews DNA Methylation and MicroRNA-Based Biomarkers for Risk of Type 2 Diabetes
Current Diabetes Reviews Chinese Herbal Formulas and Renal Fibrosis: An Overview
Current Pharmaceutical Design Risk Factors and Management of Kidney Diseases in Saudi Women with Diabetes
Current Women`s Health Reviews Recent Advances in Non-Peptidomimetic Dipeptidyl Peptidase 4 Inhibitors: Medicinal Chemistry and Preclinical Aspects
Current Medicinal Chemistry Advanced Glycation End Products: Association with the Pathogenesis of Diseases and the Current Therapeutic Advances
Current Clinical Pharmacology Patent Selections:
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Immunomodulation Mechanism of Antidepressants: Interactions between Serotonin/Norepinephrine Balance and Th1/Th2 Balance
Current Neuropharmacology Flavonoids as Potential Therapeutic Agents for the Management of Diabetic Neuropathy
Current Pharmaceutical Design The Predominant microRNAs in β-cell Clusters for Insulin Regulation and Diabetic Control
Current Drug Targets Plant Compounds for the Treatment of Diabetes, a Metabolic Disorder: NF-κB as a Therapeutic Target
Current Pharmaceutical Design Recent Advances in Drug Delivery Systems for Anti-Diabetic Drugs: A Review
Current Drug Delivery Effects of Alpha-lipoic Acid Supplementation on Human Diabetic Nephropathy: A Systematic Review and Meta-analysis
Current Diabetes Reviews Alcohol and the Cardiovascular System: A Double-Edged Sword
Current Pharmaceutical Design The Emerging Role of Arginase in Endothelial Dysfunction in Diabetes
Current Vascular Pharmacology Current Options and Perspectives in the Treatment of Diabetic Neuropathy
Current Pharmaceutical Design